Stock A249420 ILDONG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Ildong Pharmaceutical Co., Ltd.

Equities

A249420

KR7249420001

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 26/06/2024 BST 		5-day change 1st Jan Change
13,000 KRW -0.15% Intraday chart for Ildong Pharmaceutical Co., Ltd. -0.23% -28.41%
05-22 Dong-A ST to Become Second-Largest Shareholder of Idience in KRW25 Billion Deal MT
2023 Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dong-A ST to Become Second-Largest Shareholder of Idience in KRW25 Billion Deal
MT
Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea
MT
Il Dong Pharmaceutical Introduces New R&D Unit Yunovia
MT
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 30 billion in funding
CI
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 30 billion in funding
CI
Ildong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Il Dong's Application for Shionogi's COVID Oral Medication Accepted for Review in South Korea
MT
Ildong Pharmaceutical Co., Ltd. Files a New Drug Application with the MFDS for the Indication of SARS-CoV-2 Infection, and This Application Has Been Accepted for Review by MFDS
CI
Shionogi JV Sub-licenses COVID-19 Drug to South Korea's Il Dong Pharmaceutical
MT
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology
MT
Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology
CI
Ildong Pharmaceutical : Interim Report on Business Performance (Fair Disclosure)
PU
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills
MT
Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug
MT
Ildong Pharmaceutical : starts Phase 1 study of new diabetes therapy in Germany
AQ
Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany
CI
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in funding
CI
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 100 billion in funding
CI
Evotec SE and Ildong to Collaborate with Development Projects on Indigo Platform
CI
Ildong Pharmaceutical Co., Ltd. Enters into Co-Promotion Agreement with GSK Consumer Healthcare SA
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A249420 Stock
  4. News Ildong Pharmaceutical Co., Ltd.